-The Business Standard The Novartis verdict by the Supreme Court emphasised the importance of flexibilities in drug patent laws, in contrast to Western countries which are seeking TRIPS-plus hardening through free-trade agreements As curtains on the six-year-long legal tussle with Swiss drug giant Novartis AG finally came down earlier this month, the Indian government did not waste a second in hailing the Indian patent law which it said was in "full...
More »SEARCH RESULT
Glivec lesson for pharma: Patented drugs must be priced smartly-Kiran Mazumdar Shaw
-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...
More »Domestic pharma lauds apex court verdict-Reghu Balakrishnan
-The Business Standard Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up Though the India office here of Swiss pharma giant Novartis wore a gloomy look following the Supreme Court rejection of its Glivec patent application, Indian pharmaceutical companies and patients' associations are in celebration mood. D G Shah, secretary general, The Indian Pharmaceutical Alliance (IPA), comprising leading research-based Indian pharma companies, said,...
More »SC’s Glivec ruling setback to foreign pharma firms -Vidya Krishnan and CH Unnikrishnan
-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...
More »Govt working on norms to protect trade secrets -Subodh Ghildiyal & Sidhartha
-The Times of India Your favourite restaurant may soon get legal protection for its centuries old recipe with the government starting discussion on possible norms for trade secrets. The latest intellectual property right (IPR), which draws upon an established practice in several countries, may actually cover everything from manufacturing processes to sales and distribution methods, ad strategies and client and vendor lists — a move that could provide comfort to companies...
More »